Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

This trial is testing a CAR-T cell therapy that targets a protein called CEA (found on the surface of some cancer cells) for people with advanced digestive system cancers, particularly colorectal, stomach, esophageal, and pancreatic cancer. CAR-T is a cutting-edge treatment where a patient's own immune cells are engineered to attack cancer. **You may be eligible if...** - You are 18 or older - You have confirmed advanced, metastatic, or recurrent colorectal, esophageal, stomach, or pancreatic cancer - Your tumor tests positive for CEA protein (on at least 10% of cells) - You have already failed at least two lines of standard treatment - You are in reasonably good health (ECOG 0–2) - Your heart, kidney, liver, and blood counts are within acceptable ranges **You may NOT be eligible if...** - Your tumor does not express CEA - You have had only one prior line of treatment - You have serious mental illness - Your blood oxygen level is below 95% without extra oxygen - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.